Google
AQST Stock Analysis — AQUESTIVE THERAPEUTICS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
AQST FAQ
What is AQST's ROE?
AQUESTIVE THERAPEUTICS INC reports a Return on Equity (ROE) of 202.36%.
What is AQST's dividend yield?
AQUESTIVE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is AQST's Quality Score?
Our AI rates AQST's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AQST?
Our AI Timing Score for AQST is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AQST belong to?
AQUESTIVE THERAPEUTICS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
AQST AI Analysis Summary
Our AI summary for AQST: AQUESTIVE THERAPEUTICS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of 202.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.70
Price
-0.03
(-0.67%)
Day Change
|
|
|---|
AQST, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.70 |
| PBV / Sector |
-13.71 / 3.22
|
| Earning Per Share | -0.55 |
| PE / Sector |
N/A / 29.79
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
7.23 M
|
| Average 1W Daily Value |
7.69 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:29 |
| Symbol | AQST |
| Name | AQUESTIVE THERAPEUTICS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 125.47 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 466.74 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 30 Technology Drive, Warren, NJ, United States, 07059
Phone: 908 941 1900
Website: https://www.aquestive.com
Employees: 147
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap